On Nov. 5, 2015, TapImmune, (TPIV) announced it had relocated its corporate headquarters from Seattle, Washington, to Jacksonville, Florida. The company, formerly known as GeneMax, was founded in Vancouver, BC based on technology from the University of British Columbia.

TPIV was a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease. In 2018, TapImmune merged with privately-held Marker Therapeutics.